The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril. by Turini, G.A. et al.
European Heart Journal (1983) 4 (Supplement A), 189-197
The renin-angiotensin system in refractory heart
failure: clinical, hemodynamic and hormonal effects of
captopril and enalapril
G. A. TURINI, B. WAEBER AND H. R. BRUNNER
Department of Medicine, Centre Hospitaller Universitaire Vaudois, Lausanne, Switzerland
KEY WORDS: Congestive heart failure, saralasin, captopril, enalapril (MK 421), renin, angiotensin,
norepinephrine, hemodynamics.
Studies using a competitive inhibitor of angiotensin II (saralasin) or converting enzyme inhibitors (teprotide,
captopril, enalapril) have established that the renin-angiotensin system participates in the control of vascular tone
in congestive heart failure both in experimental settings and in patients. In man, the marked decrease in left
ventricular filling pressure and the variable increase in stroke volume induced by renin—angiotensin blockade
suggests that angiotensin II actively constricts venous as well as arteriolar vascular beds. Captopril, in doses of 25
to 150 mg p.o. TID, maintains its efficacy during chronic administration with persistent clinical and hemodynamic
improvement as well as increased exercise tolerance. In our experience, enalapril, 10 mg p.o., improves cardiac
function within 4 to 6 h as reflected by a 30% decrease in left ventricular filling pressure, a 28% increase in stroke
volume in the face of unchanged heart rate. Clinical improvement, enhanced exercise tolerance and characteristic
hormonal responses suggest that enalapril also maintains its efficacy during long-term treatment. Chronic
angiotensin II converting enzyme inhibition appears lobe a major advance in the treatment of patients with severe
congestive heart failure, refractory to digitalis and diuretics.
In patients with congestive heart failure, the
occurrence of a compensatory increase in venous and
arteriolar tone often causes further deterioration in
pump performance. The factors responsible for this
vasoconstriction include enhanced sympathetic nerve
activity and possibly hyperreactivity of the vascular
wall to pressor stimuli. The renin-angiotensin system
also has been shown to participate in the complex
regulation of vascular tone of such patients.
Patients with congestive heart failure frequently
fail to excrete sodium and lack the ability to maintain
normal sodium balance. Because angiotensin II is a
major stimulus of aldosterone secretion, it could
theoretically be expected that blockade of the renin-
angiotensin system might also reverse to some extent
sodium retention. The purpose of this report is to
review the role of renin in congestive heart failure and
the clinical efficacy of various drugs inhibiting the
renin angiotensin system, including enalapril, a new
orally active converting enzyme inhibitor.
Requests for reprints w G. A. Tunni. M D . Dept. of Medicine.
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The renin-angiotensin system in congestive heart
failure
The secretion of renin is stimulated by sodium
depletion, decreased renal perfusion and increased
sympathetic nerve activity'". In the plasma, renin
acts on renin substrate to produce angiotensin I
which is converted, mostly at the level of the
pulmonary circulation, to its active form angiotensin
II by a converting enzyme. Angiotensin II, a powerful
vasoconstrictor, stimulates aldosterone secretion by
the adrenal cortex and acts directly in the brain to
elicit thirst121. Thus stimulation of the renin-angio-
tensin-aldosterone hormonal system may increase
systemic vascular resistance and total body fluid and
sodium.
It has been shown in animals with experimental
congestive heart failure due to pressure or volume
overload, that the renin-angiotensin system is actively
implicated in the maintenance of blood pressure13 ~7'.
In these animals, plasma renin activity and aldo-
sterone rose markedly immediately following
development of heart failure and ensuing hypo-
0195- 668X/83/04A189 + 09 $02 00/0 i 1983 The European Society of Cardiology
190 G. A. Turini, B. Waeber and H. R. Brunner
tension. As a consequence, plasma volume increased,
blood pressure was restored to normal and both
plasma renin activity and aldosterone returned to
baseline values. Some animals, however, did not
reach their control arterial pressure and showed a
persistent increase in plasma renin activity and
aldosterone13'.
Studies of patients with chronic heart failure
refractory to digitalis and diuretics have revealed
plasma renin activity varying from low to very high
levels'8"10'. Frequently, patients with heart disease
due to different etiologies and with a wide range of
clinical severity were pooled for analysis. It is not
ruled out, however, that the activity of the
renin-angiotensin system in congestive heart failure"
may well vary according to the cause of heart failure.
On the other hand, plasma renin activity appears more
consistently elevated during episodes of acute cardiac
decompensation than in the chronic stage of heart
failure11".
In the past, the best way to evaluate the function of
a hormone was to unmask its action by removing the
organ producing it. Accordingly, the role of the renin
system has been investigated by binephrectomy,
obviously a very crude and non-specific approach. In
the early seventies, the development of agents
antagonizing the effect of renin has opened a new,
more physiological way to study the role of the
renin-angiotensin system. Such inhibitors act either
at the receptor level as competitive antagonists or
angiotensin II (saralasin)"2', or in blocking the
enzyme which converts the inactive angiotensin I into
the active octapeptide angiotensin II (teprotide,
captopril, enalapril)"3"15 ' .
Competitive angiotensin II blockade
In our laboratory, saralasin (Eaton laboratories)
was administered to 15 patients with congestive heart
failure due to various etiologies'101. Figure 1 shows
the relationship between left ventricular filling
pressure and stroke index in 13 of them, before and
duringsaralasininfusion(1-10 ng kg" ' min~'). Eight
patients decreased their blood pressure, whereas five
did not change or even increased it. Left ventricular
filling pressure fell in all but one, often with no
change and sometimes with an increase in stroke
index. The marked fall in left ventricular filling
pressure cannot be explained solely by a decrease in
arteriolar tone and impedance but strongly suggest,
in addition, a decrease in venous tone.
The initial plasma renin activity of the patients
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Figure I Left ventricular function curves of 13 patients who
had an infusion of saralasin. O, A = before and • .
A = after saralasin All but one patient who had increased
arterial pressure experienced improvement in left ventricular
function. From Turini el «/.<10).
according to their arterial pressure response to
saralasin is illustrated in Fig. 2. Those patients whose
arterial pressure did not decrease had a mean plasma
renin activity of 20±0-58 ng ml" ' , a value not
significantly different from that of five controls. In
contrast, patients responding with a fall in arterial
pressure had a mean plasma renin activity of 8-1 + 1-6
ng/ml (mean + s.e.m.). Some patients with
I 5 r
I
~ 10
.E
"o
o
c
c
? 5 -
-
"
D
0
l-o
0
o
0
"o
0
o
O
o
A
A
A
Controls CHF
B P | by
•arabsin
CHF
BP—or t
by saralasin
Figure 2 Initial plasma renin activity of controls ( • ) . and
patients with congestive heart failure who had a decrease
(O) or no change or an increase (A) in arterial pressure in
response to saralasin infusion. The patients who had a
decrease in blood pressure had significantly higher renin
levels (P<0 01). From Turini el a/."01.
i
Renin-angioiensin system 191
}
apparently 'normal' plasma renin activity also
responded with a fall in arterial pressure.
This study of saralasin has established for the first
time that the renin-angiotensin system plays an
important role in controlling pre- and afterload of
patients with congestive heart failure1161. Further-
more, it has demonstrated that angiotensin II
blockade improves pump function of the heart in
most cases. This may have come as a certain surprise
since angiotensin II had been reported to exert a
positive inotropic effect"7181. The study of saralasin
is of particular interest, since this compound, which is
a competitive antagonist of angiotensin II at the
receptor level, is the most specific inhibitor of the
renin system. Saralasin has, however, the short-
coming of many competitive antagonists, that is to
have agonistic or angiotensin II-like properties,
which can lead to an increase in vascular tone under
certain circumstances, e.g. when plasma renin activity
is very low"01. Moreover, since it is an octapeptide
with a relatively short half-life, it has to be infused
intravenously which makes it unsuitable for long-
term therapy.
Angiotensin converting enzyme inhibition
The first converting enzyme inhibitor available for
clinical investigation, teprotide, is a nonapeptide and
must therefore also be administered parenterally
which renders chronic blockade impractical in
patients. Its acute effect has been evaluated in
patients with congestive heart failure"9 '20 '. The
results of these studies were similar to those obtained
with saralasin, though suggesting a more pronounced
arteriolar dilatation following converting enzyme
inhibition.
CAPTOPRIL
In 1976, captopril (E.R. Squibb), the first orally
active converting enzyme inhibitor, became avai-
lable11*1. When it was administered to normal
volunteers, 20 mg p.o. was sufficient to block within
15 min for over 2 h the pressor response to exogenous
angiotensin I<21).
Captopril was then given to patients with severe
refractory heart failure'22"281. The doses used varied
between 6-25 and 150mg p.o. Within 1 to 3 h, a
significant fall in mean arterial pressure, in left
ventricular filling pressure and in right atrial pressure
was observed. The decrease in left ventricular filling
pressure ranged from 20 to 45%. Simultaneously,
stroke index rose by 15 to 30% while heart rate was
not accelerated. All indices returned to baseline
within 3 to 8 h after drug administration depending
on the dose.
The marked decrease in left ventricular filling
pressure with a variable increase in stroke index
observed in most patients suggests that captopril acts
both on the arterial and the venous side of the
circulation. The decrease in systemic vascular
resistance and mean arterial pressure was not
unexpected, since captopril has been used extensively
to reduce the blood pressure of hypertensive patients.
The fall in preload may have been less expected since
there still exists some controversy on whether
angiotensin II induces venous constriction'21. The
effect of converting enzyme inhibition on the venous
side could also be indirectly mediated. Indeed,
angiotensin II can stimulate sympathetic nerve
activity via a central mechanism and in addition
facilitate norepinephrine release by terminal nerve
endings. It is therefore noteworthy that converting
enzyme inhibition has been shown to decrease plasma
norepinephrine levels in some patients with conges-
tive heart failure"9'221 whereas, in contrast, the
plasma concentration of this hormone has been
reported to increase after discontinuation of captopril
therapy'291. It is also possible that captopril interferes
with the pressor action of catecholamines.
Thus, we have observed in the rat a decrease in the
pressor response to norepinephrine following capto-
pril administration'301. Since angiotensin converting
enzyme is also partly responsible for the inactivation
of bradykinin'3" the decrease in preload could
theoretically be attributed to accumulation of
vasodilating hormone. However, in experimental
studies, we have not found any evidence for a
bradykinin mediated effect of captopril'321. More-
over, saralasin is also known to decrease preload
although it is not believed to influence bradykinin
metabolism"01. Thus, bradykinin probably does not
play an important role in the captopril mediated
effect on preload and it seems more likely that this is
related to decreased angiotensin II levels.
In many patients with congestive heart failure,
measured plasma renin activity was not a reliable
predictor of the hemodynamic response to renin
angiotensin inhibition. To date, it is still not clear
which factors govern renin secretion nor what
determines vascular sensitivity to angiotensin II in
patients with congestive heart failure. As a conse-
quence it is not possible to determine what renin level
is appropriate for a given hemodynamic state.
Accordingly, it is also not surprising that in some
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patients with seemingly 'normal' plasma renin
activity, blockade of the renin-angiotensin system
induced a marked improvement in cardiac function.
Thus, in patients with congestive heart failure, the
measurement of plasma renin activity has serious
limitations when used as an index of the physiological
role of the system.
Though many patients with congestive heart failure
have been treated with captopril for a prolonged
period of time, relatively few long-term hemodynamic
results have been published so far. Table 1 sum-
marizes hemodynamic studies in a total of 52 patients
carried out after two to six months of captopril 25 to
150 mg p.o. t.i.d.'25-26"-341. The table demonstrates
that the hemodynamic improvement persists in this
group of severely ill patients and that there exists no
real tachyphylaxis. It is of note that the magnitude of
the acute hemodynamic effect has not been a good
predictor of the long-term response to captopril.
Sustained hemodynamic improvement has also been
documented by radionuclide studies'351.
During chronic captopril administration,
numerous investigators have observed a persistent
and marked increase in exercise tolerance as assessed
by ergometry125"27-361. These changes seem to have
been statistically significant, also when compared to
placebo controls (E.R. Squibb, pers. comm.).
Subjective improvement has been very striking, often
within 1 h of drug administration, even in patients
with only modest improvement of hemodynamics.
Such an effect was never observed during saralasin
administration and one might wonder if it could be
due to activation of enkephalins by the converting
enzyme inhibition1371. Captopril being a drug with a
relatively short duration of action, it could be feared
that its sudden discontinuation induces a rebound
phenomenon. Fortunately such a withdrawal
syndrome does not seem to occur1291.
Among 498 patients with congestive heart failure
treated for up to two years (E.R. Squibb, pers.
comm.), arterial hypotension has been observed in
24% and skin rash and/or pruritus in 7%. One to 3%
have experienced taste alteration, gastrointestinal
discomfort or renal impairment which may lead to
hyperkalemia. In our experience hyperkalemia and
hypotension is best avoided by decreasing or stopping
diuretic therapy before starting captopril therapy.
Similarly symptomatic hypotensive episodes during
captopril treatment can be managed by temporarily
reducing or interrupting administration of diuretics.
Other side-effects usually subside when the dose is
decreased.
ENALAPRIL
Many new converting enzyme inhibitors are
currently under investigation'38-39'. Among those,
enalapril (MK 421, Merck Sharp and Dohme)
appears to be particularly potent. In normal
volunteers, 10 mg p.o. were sufficient to block the
response to exogenous angiotensin I within 2 to 4 h
and the effect lasted for more than 10 h'401.
We recently investigated five men and one woman
aged 55 to 72 with class III (four patients) or IV (two
patients) chronic congestive heart failure despite salt
restriction, digitalis and diuretic treatment. Before the
study, all patients were on a constant salt intake of 2
to 3 g/day. Digoxin was maintained whereas the
diuretic was interrupted on the morning of the
procedure. After an overnight fast, the patients
underwent cardiac catheterization in the supine
position. A Swan-Ganz and a short polyethylene
arterial catheter were introduced percutaneously.
Pressures were measured with Statham P23Dd
transducers and recorded on a Hewlett Packard
14560 recorder. Cardiac output was measured by
thermodilution with a Roche Bioelectronic model
535095 monitor, using injections of 5 ml of iced
isotonic solution. After a rest period of 45 min,
baseline hemodynamic measurements were obtained.
Then, lOmg of enalapril was given by mouth and
hemodynamic measurements were repeated every
hour for a minimum of 4 h. Blood samples were
drawn before and 4 h after enalapril administration.
The following parameters were measured in the
plasma: renin activity'4'•42\ angiotensin converting
enzyme activity141431, angiotensin H140-44', aldo-
sterone'41 '4", plasma norepinephrine and epine-
phrine levels'461. Before cardiac catheterization, four
patients underwent an exercise tolerance test on a
treadmill using the Naughton protocol'47' with the
modification that each step lasted only 2 min. After
two months of therapy, exercise tolerance test and
plasma measurements were repeated in these
patients.
Figure 3 summarizes the hemodynamic response to
enalapril. Within 4 to 6 h, at the time of maximum
effect, mean arterial pressure had decreased from an
initial 85 + 4-2 to 72±3-2mmHg (mean±s.e.m.)
with a concomitant fall in pulmonary capillary wedge
pressure from 20±2-8 to 14±2-8 mm Hg (P<0001)
while cardiac index had increased from 1-5±006 to
l -8±01 l m i n - ' r r T 2 (P - 005) due to a rise in
stroke index from 18±1-7 to 23 + 2-5 ml m~2
(P<005) . Heart rate did not change. Right atrial
pressure decreased from 8±2-4 to 6+1-9 mm Hg
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Figure 3 (a) Mean blood pressure, (b) pulse rate, (c)
pulmonary capillary wedge pressure and (d) cardiac index of
six patients with refractory congestive heart failure before
(O) and 4-6 h following administration of enalapril
(MK42I) lOmgp.o. (#). *P<005. •**/><0-001. Results
are mean ±s.e.m.
0-005). The decrease in arterial pressure was well
tolerated by all patients.
The relationship between stroke index and
pulmonary capillary wedge pressure before enalapril
administration and at the time of peak effect (4 to
6 h), is shown in Fig. 4. A fall in left ventricular filling
pressure coincided with an increase in stroke index in
five patients and with no change in one. These results
suggest that enalapril like captopril reduces both
arteriolar and venous tone.
The time sequence of the changes in mean arterial,
right atrial and pulmonary capillary wedge pressure
as well as in cardiac index following oral adminis-
tration of 10 mg enalapril is illustrated in Fig. 5.
Compared to the effect of captopril, onset of action
was slower and peak effect was not reached before
4 h, when many patients treated with captopril have
already returned to baseline conditions.
Figure 6 depicts hormonal measurements before
and 4 h after the initial enalapril administration
in four patients studied on a long-term bases.
Plasma renin activity rose from 8-4 + 31 to 31 ±
13-1 ngml"1 h~ ' . Plasma angiotensin converting
30
25
I 20
15
10
1
10 15 20 25
Pulmonary capillary wedge pressure (mm Hg)
Figure 4 Relationship between pulmonary capillary wedge
pressure and stroke volume index before (O) and 4-6 h
following administration of enalapril (MK 421) 10 mg p.o.
NK. 421 10 mg po
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Figure 5 Time sequence during the initial 4 h of changes in
(a) mean blood pressure, (b) right atrial pressure, (c)
pulmonary capillary wedge pressure and (d) cardiac index
following administration of enalapril (MK 421) 10 mg p o.
n = 6. Results are mean + s.e m.
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Figure 6 Plasma levels of (a) renin activity, (b) aldosterone,
(c) angiotensin II, (d) converting enzyme activity, (e)
norephinephrine and (f) epinephrine before and 4 h after the
acute administration of enalapril (MK 421) 10 mg p.o. The
same parameters were remeasured after two months of
enalapril therapy, 10 mg p.o. b.i.d., before and 4 h after the
morning dose of enalapril. n = 4. Results are mean ± s.e.m
enzyme activity fell from 125±11 to 5 ± 2 nmol ml ~'
min~\ plasma aldosterone from 26±3-3 to 7-5±
1-3 ngdl~ ' and plasma norepinephrine from 0-59 +
0-21 to 0-47 + 011 ngml"1 . Plasma epinephrine
was very low at 005 ± 0 0 2 ngml" ' and did not
change.
All six patients were placed on chronic treatment
consisting of 10 mg q.d. or b.i.d. They all reported a
marked decrease in symptoms and a net subjective
improvement in functional capacity. In 4 of these
chronically treated patients, plasma renin activity had
returned to the pre-treatment mean of 8-8±40
n g m l ~ ' h ~ ' whereas plasma aldosterone,
angiotensin II, angiotensin converting enzyme
activity and norepinephrine remained markedly
decreased (Fig. 6).
Each of the four patients, in whom a treadmill test
was performed before enalapril treatment, increased
his exercise capacity during long-term converting
enzyme inhibition. This improvement was similar to
that seen in patients after two months of treatment
with captopril (Fig. 7). Indeed, all patients increased
their treadmill performance by at least two stages.
Thus, in patients with chronic refractory congestive
- JT]
•
Control CEI
7-8 Weeks
Figure 7 Exercise capacity according to a modified
Naughton protocol before and after two months of
treatment by captopril ( ) or enalapril ( ).
heart failure enalapril acutely enhances hemodyna-
mic function by decreasing both preload and
afterload. The clinical improvement, the increased
exercise tolerance and the sustained hormonal effects
observed after several weeks of therapy suggest that
the effect of enalapril, like that of captopril, persists
with long-term administration.
Conclusions
During the past decade, specific antagonists of the
renin-angiotensin system have been developed.
Saralasin is a competitive inhibitor of angiotensin II
at the receptor level and teprotide, captopril and
enalapril block the angiotensin converting enzyme
and thereby the generation of angiotensin II. All
these compounds have been administered to patients
with chronic refractory congestive heart failure and
have produced a marked improvement of cardiac
pump function. On the one hand, this strongly
suggests that the renin-angiotensin system contri-
butes to the excessive arteriolar and venous
constriction characteristic of refractory congestive
heart failure. On the other hand, chronic converting
enzyme inhibition by captopril appears to provide a
major advance in the treatment of these patients.
Unlike vasodilators, it does not induce sodium
retention, and neither tachyphylaxis nor rebound
after discontinuation have been observed. Enalapril is
a more recently developed converting enzyme
inhibitor with a slower onset and a longer duration of
action. Its hemodynamic effects are very similar to
those of captopril and its beneficial effects in patients
with congestive heart failure persist with prolonged
therapy.
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